H. Mutlu Et Al. , "Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer," CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5, pp.546-548, 2012
Mutlu, H. Et Al. 2012. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5 , 546-548.
Mutlu, H., Berk, V., Karaca, H., Erden, A., Aslan, T., & Akca, Z., (2012). Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5, 546-548.
Mutlu, Hasan Et Al. "Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer," CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5, 546-548, 2012
Mutlu, Hasan Et Al. "Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5, pp.546-548, 2012
Mutlu, H. Et Al. (2012) . "Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer." CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , vol.18, no.5, pp.546-548.
@article{article, author={Hasan Mutlu Et Al. }, title={Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer}, journal={CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS}, year=2012, pages={546-548} }